Clinical Team
Mingdong Zhou, Ph.D.

Dr. Zhou is the founder, CEO and Chief Scientist of Zensun. Dr. Zhou earned his B.S. in biology from Fudan University in 1982 and his Ph.D. in cellular and molecular biology from New York State University in 1992. After he completed postdoctoral research training at the University of California, San Diego in 1996, he moved to Sydney, Australia, where he headed the Cell Signaling Laboratory of the Victor Chang Cardiac Research Institute. He discovered important effects of neuregulins in maintaining cardiomyocyte structure and function, as well as the fact that ErbB2/ErbB3 hetero-dimerization is essential for tumor development. Dr. Zhou has authored more than 30 original research papers in PNAS, JACC, JBC, Circulation Research, and other international journals. He has applied for 174 patents, 61 of which have been granted, including 41 world-wide and 20 patents in China. In 2000, Dr. Zhou returned to China and founded Zensun (Shanghai) Sci. & Tech. Co., Ltd. Zensun focuses on leading-edge research and development of mechanism-based healthcare solutions. The current pipeline includes cardiovascular disease treatment, anti-cancer drugs, and treatments for energy metabolism disorders. The first-in-class drug Neucardin™, which addresses wholly innovative targets and mechanisms, is now in phase III clinical trials and will bring revolutionary innovations in cardiomyocyte therapy. After more than ten years of research and development, Zensun’s product line of innovative drugs and medical instruments with short, medium, or long term horizons for commercialization is ready to begin appearing in the global market, and Zensun will become an integrated company doing research, production, and sales.

Run-Lin Gao M.D.
Principal Investigator of Neucardin™’s Phase II& III Clinical Trial in China
Dr. Gao is the principal investigator of all the clinical trials for NeucardinTM that have been conducted in China. He worked as the head of the Cardiovascular Disease Institute of the Chinese Academy of Medical Sciences and Fuwai Hospital, and is now taking responsibility as the Vice Chairman of the Chinese Doctor Association, Standing Director of the Chinese Medical Association, FACC, and Chief Editor of the Chinese Medical Journal. Professor Gao was the first to perform emergency percutaneous transluminal coronary angioplasty for acute myocardial infarction and the first to report the use of coronary stenting and drug-eluting stents in China. He has received seven academic awards, and has more than 490 original publications.
Professor Barry H. Greenberg, MD, Ph.D.
Chair of the Advisory Board for Neucardin™’s Clinical Trials
Dr. Greenberg is currently Professor of Medicine at UCSD School of Medicine and Director of the Advanced Heart Failure Treatment Program at UCSD. He is also a charter member of the UCSD/Salk Institute of Molecular Medicine. He is a founding member and former vice president of the Heart Failure Society of America. He is a member of the advisory board for Neucardin™’s clinical trials. Dr. Greenberg leads an active research program investigating basic mechanisms and new treatment methods involved in heart failure. He serves on the Editorial Board for many famous cardiology journals and is an editor of Congestive Heart Failure and an associate editor of the Journal of the American College of Cardiology. Dr. Greenberg has been consistently selected as one of the "Best Doctors in America" for many years.
Professor Inder Anand, MD, Ph.D.
Member of the Advisory Board for Neucardin™’s Clinical Trials
Dr. Anand received his Ph.D. degree in cardiovascular physiology from Oxford University and is a professor at the University of Minnesota. He is the chairman of the heart failure group. He is an advisor for global clinical trials for Neucardin™. He has been active in designing and conducting clinical trials in heart failure over the last twenty years. He has been a principal investigator in over 50 heart failure clinical trials, and a member of steering and end-point committees on several of these international trials. He is a member of the editorial board for several scientific journals and has authored over 300 publications with over 1,000 citations of his published work.
Robin Allgren, MD, Ph.D.
Chief Medical Officer
Dr. Allgren received her Ph.D. degree from Stanford University and her MBA from Golden Gate University. She has more than 25 years of experience, spanning the biotech, pharmaceutical, medical devices, and diagnostics industries. She successfully executed clinical development activities from preclinical stages through IND filing, NDA filing, and approval. She also has great expertise in pharmacovigilance. She has now taken responsibility as CMO in Zensun USA.
Xiaorui Wang, Ph.D.
Vice President, Regulatory Affairs and Clinical Development
Dr. Wang graduated from National University of Singapore with a Ph.D. in biochemistry in 2013. Before joining Zensun, she worked at Singapore Bioimaging Consortium, Agency for Science, Technology, and Research (A*STAR) from 2007 to 2014 as a senior research officer and worked on diabetes and obesity area. Her current role covers regulatory affairs and clinical development.
Lei Zhang, Ph.D.
Vice President, Zensun USA, Global Clinical Development & Operations
Dr. Zhang serves as VP of Global Clinical Development & Operations at Zensun USA overseeing global clinical studies. Dr. Lei Zhang has over 15 years of experience in clinical & medical affairs that span across the medical device, biotechnology, and diagnostic industries. Prior to Zensun, Dr. Zhang held management positions in Clinical & Medical Affairs and R & D at Alere, Cytori Therapeutics, Inovio Biomedical, Halozyme Therapeutics and Genetronics, Inc. Dr. Zhang earned her Ph.D. in from Friedrich-Shiller Univ. in Germany.
Clinical Trials Recruiting Participants